Brokerages expect Mesoblast limited (NASDAQ:MESO) to post $1.31 million in sales for the current fiscal quarter, according to Zacks Investment Research. Two analysts have made estimates for Mesoblast’s earnings. The highest sales estimate is $1.61 million and the lowest is $1.00 million. Mesoblast reported sales of $13.40 million during the same quarter last year, which would suggest a negative year-over-year growth rate of 90.2%. The business is scheduled to issue its next quarterly earnings report on Tuesday, February 26th.
According to Zacks, analysts expect that Mesoblast will report full-year sales of $9.08 million for the current financial year, with estimates ranging from $3.00 million to $17.45 million. For the next fiscal year, analysts expect that the business will post sales of $47.84 million, with estimates ranging from $10.00 million to $85.67 million. Zacks’ sales calculations are an average based on a survey of research analysts that cover Mesoblast.
MESO has been the subject of several research analyst reports. Cantor Fitzgerald set a $23.00 target price on shares of Mesoblast and gave the stock a “buy” rating in a research report on Monday, October 1st. Zacks Investment Research cut shares of Mesoblast from a “buy” rating to a “hold” rating in a research report on Wednesday, October 31st. Maxim Group reaffirmed a “buy” rating and issued a $16.00 target price on shares of Mesoblast in a research report on Monday, November 12th. Oppenheimer set a $15.00 target price on shares of Mesoblast and gave the stock a “buy” rating in a research report on Monday, November 12th. Finally, ValuEngine raised shares of Mesoblast from a “hold” rating to a “buy” rating in a research report on Wednesday, September 26th. Two research analysts have rated the stock with a sell rating and five have given a buy rating to the company. The stock currently has an average rating of “Hold” and a consensus price target of $13.96.
Hedge funds and other institutional investors have recently modified their holdings of the stock. Jane Street Group LLC bought a new stake in Mesoblast during the 3rd quarter valued at about $117,000. Citadel Advisors LLC bought a new stake in Mesoblast during the 3rd quarter valued at about $215,000. Renaissance Technologies LLC increased its stake in Mesoblast by 249.8% during the 3rd quarter. Renaissance Technologies LLC now owns 165,161 shares of the company’s stock valued at $1,348,000 after purchasing an additional 117,951 shares in the last quarter. Finally, Capital World Investors bought a new stake in Mesoblast during the 3rd quarter valued at about $3,695,000. 3.00% of the stock is owned by institutional investors.
Mesoblast Company Profile
Mesoblast Limited, a biopharmaceutical company, develops and commercializes allogeneic cellular medicines. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage adult stem cells. The company's products under the Phase III clinical trials include MSC-100-IV for steroid refractory acute graft versus host disease; MPC-150-IM for advanced heart failure; and MPC-06-ID for chronic low back pain due to degenerative disc disease.
Recommended Story: Why is insider trading harmful?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Mesoblast Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mesoblast and related companies with MarketBeat.com's FREE daily email newsletter.